TAK-438 belongs to a new class of inhibitors called potassium-competitive acid blockers (P-CABs) that show strong and sustainable acid secretion inhibitory effects as well as demonstrate efficacy in early termination by inhibiting the binding of potassium ion (K+) to H+, K+-ATPase (proton pump) in the final step of gastric acid secretion in gastric parietal cells.
In this early stage of our company, we develop a synthesis process which can obtain TAK-438 in the batch of >100g scale. And we have the compound(>98% By HPLC) in stock now. Look forward to your cooperation.
Copyright © 2014-2015 Tubepharm. All Rights Reserved.
Tel：+86 021 5433 8626 Fax：+86 021 5433 8626*801 E-mail: firstname.lastname@example.org
All of our products, unless clearly indicated otherwise, are sold for research or manufacturing purposes only, are not for human, veterinary and household use.
The products under valid patent protection are not offered at this time. It is fully client's responsibility to comply with the rules, regulations and patent laws.